IVVD (Invivyd) Cash-to-Debt : 53.18 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Invivyd Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Invivyd's cash to debt ratio for the quarter that ended in Dec. 2024 was 53.18.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Invivyd could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for Invivyd's Cash-to-Debt or its related term are showing as below:

IVVD' s Cash-to-Debt Range Over the Past 10 Years
Min: 53.18 Med: 99.89 Max: No Debt
Current: 53.18

During the past 5 years, Invivyd's highest Cash to Debt Ratio was No Debt. The lowest was 53.18. And the median was 99.89.

IVVD's Cash-to-Debt is ranked better than
72.29% of 1487 companies
in the Biotechnology industry
Industry Median: 7.48 vs IVVD: 53.18

Invivyd Cash-to-Debt Historical Data

The historical data trend for Invivyd's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Invivyd Cash-to-Debt Chart

Invivyd Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

No Debt

99.89

92.68

53.18

Invivyd Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial													92.68	107.67	217.15	65.44	53.18

Competitive Comparison of Invivyd's Cash-to-Debt

For the Biotechnology subindustry, Invivyd's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invivyd's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invivyd's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Invivyd's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Invivyd Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Invivyd's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	69.349	/	(1.304	+	0)
	=	53.18

Invivyd's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	69.349	/	(1.304	+	0)
	=	53.18

Invivyd (NAS:IVVD) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Invivyd Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Invivyd's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Invivyd Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invivyd Inc (NAS:IVVD) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

1601 Trapelo Road, Suite 178, Waltham, MA, USA, 02451

Website

https://www.invivyd.com

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Executives

Terrance Mcguire	director, other: See Remarks	C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
Adimab, Llc	10 percent owner, other: See Remarks	7 LUCENT DRIVE, LEBANON NH 03766
William E. Duke	officer: Chief Financial Officer	C/O VALERITAS, INC., 750 ROUTE 202 SOUTH, SUITE 600, BRIDGEWATER NJ 08807
Sara Cotter	director	1735 MARKET STREET, FLOOR 23, PHILADELPHIA PA 19103
Allen Robert D. Iii	officer: Chief Scientific Officer	1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Stacy Price	officer: Chief Tech. and Manuf. Officer	1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Jeremy Gowler	officer: COO & CCO	1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Rebecca Dabora	officer: Chief Tech and Manuf Officer	303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Peter Schmidt	officer: Chief Medical Officer	1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Jill Andersen	officer: Chief Legal Officer, Secretary	303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Christine Lindenboom	director	1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Frederick W Driscoll	officer: Interim CFO
David Hering	director, officer: Chief Executive Officer	303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Marc Elia	director, other: See Remarks	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
M28 Capital Management Lp	other: See Remarks	700 CANAL STREET, 2ND FLOOR, STAMFORD CT 06902